# EDGAR Filing Document

**Accession Number:** 0001280776
**File Stem:** 0001193805-25-001239
**Filing Date:** 2025-8
**Character Count:** 31055
**Document Hash:** 1cc98a60ef8e5d6772bd67798ce55e6b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193805-25-001239.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001193805-25-001239

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250827

**DATE AS OF CHANGE**: 20250827

**EFFECTIVENESS DATE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMMUNIC, INC.
- **CENTRAL INDEX KEY:** 0001280776
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 562358443
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289884
- **FILM NUMBER:** 251265245

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 200
- **CITY:** NEW YORK
- **STATE:** X1
- **ZIP:** 10036
- **BUSINESS PHONE:** (332) 255-9818

**MAIL ADDRESS:**
- **STREET 1:** 1200 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 200
- **CITY:** NEW YORK
- **STATE:** X1
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VITAL THERAPIES INC
- **DATE OF NAME CHANGE:** 20040219

**As filed with the Securities and Exchange Commission on August 27, 2025**

**Registration No. 333-**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM S-8** 

**REGISTRATION STATEMENT**

**UNDER** 

**THE SECURITIES ACT OF 1933** 

**Immunic, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **56-2358443** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**1200 Avenue of the Americas, Suite 200**

**New York, NY 10036**

**(Address, including zip code, of registrant's principal executive offices)** 

**Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as amended**

**(Full title of the plan)** 

**Daniel Vitt**

**Chief Executive Officer** 

**Immunic, Inc.** 

**1200 Avenue of the Americas, Suite 200**

**New York, NY 10036**

**(332) 255-9818**

**(Name and address, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Ilan Katz, Esq.** 

**Dentons US LLP** 

**1221 Avenue of the Americas** 

**New York, New York 10020** 

**(212) 632-5556** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**EXPLANATORY NOTE**

On April 20, 2025, the Board of Directors of Immunic, Inc. (the "Registrant") approved, subject to stockholder approval, an amendment (the "Amendment") to the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as amended (as amended, the "2019 Plan"), to increase the number of shares of common stock, par value $0.0001 per share (the "Common Stock") authorized for issuance by 7,000,000 shares to a total of 26,448,871 shares of its common stock.

On June 4, 2025, the Registrant's stockholders approved the Amendment. The Registrant is filing this Registration Statement on Form S-8 for the purpose of registering an additional 7,000,000 shares of its Common Stock, issuable to eligible persons under the 2019 Plan, which shares are in addition to the shares registered on the Registrant's registration statements on Form S-8 filed on [September 20, 2019](https://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_s8-immunic.htm) (File No. 333-233864), [August 21, 2023](https://www.sec.gov/Archives/edgar/data/1280776/000119380523001200/e618885_s8-immunic.htm) (File No. 333-274099), and [July 2, 2024](https://www.sec.gov/Archives/edgar/data/1280776/000119380524000874/e663743_s8-immunic.htm) (File No. 333-280661, and collectively with File No. 333-233864 and File No. 333-274099, the "Prior Registration Statements").

This Registration Statement relates to the registration of additional securities of the same class as that to which the Prior Registration Statements relate, and are submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2019 Plan, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The following documents filed with the SEC are hereby incorporated by reference in this registration statement:

a. Our Annual Report on Form 10-K for the fiscal year ended [December 31, 2024](https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm) , filed with SEC on March 31, 2025;

b. Our Quarterly Reports on Form 10-Q for the quarter ended [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000008/vtl-20250331.htm) , filed with SEC on May 15, 2025 and for the quarter ended [June 30, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm) , filed with the SEC on August 7, 2025;

c. The Current Reports on Form 8-K filed with the SEC on [January 13, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000038/e664134_8k-immunic.htm) , [February 20, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/e664213_8k-immunic.htm) , [April 9, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000454/e664373_8k-immunic.htm) , [April 30, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000582/e664445_8k-immunic.htm) , [May 28, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000730/e664552_8k-immuniclaunch.htm) , [May 30, 2025](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000757/e664551_8k-immunicpricing.htm) , [June 4, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000119380525000787/e664589_8k-immunic.htm) , [June 27, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000119380525000943/e664657_8k-immunic.htm) , [July 11, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001280776/000119380525001008/e664690_8k-immunic.htm) and [August 7, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000119380525001164/e664768_8k-immunic.htm) ; and

d. The description of the registrant's common stock contained in the registrant's registration statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1280776/000119312513443030/d631014d8a12b.htm) , filed by the registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on November 13, 2013, including any amendments or reports filed for the purpose of updating such description.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

**Item 4.** **Description of Securities.**

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.**

Not applicable.

**Item 6.** **Indemnification of Directors and Officers.**

We are incorporated under the laws of the state of Delaware. Section 145(a) of the Delaware General Corporation Law (the "DGCL") provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, joint venture, trust or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

Further subsections of DGCL Section 145 provide that:

(1) to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys' fees, actually and reasonably incurred by such person in connection therewith;

(2) the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and

(3) the corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145 of the DGCL.

Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify our officers and directors under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act of 1933, as amended (the "Securities Act"). Our bylaws provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, we will indemnify any person (and the estate of any person) who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or officer of our company or is or was serving at our request as a director or officer of another corporation or enterprise. We may, in our discretion, similarly indemnify its employees and agents.

We have entered into indemnification agreements with our officers and directors.

Our certificate of incorporation relieves our directors from monetary damages to us or our stockholders for breach of such director's fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for acts or omissions not in good faith, or which involve intentional misconduct or a knowing violation of law, (iii) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends, or (iv) for any transactions from which the director derived an improper personal benefit.

We currently maintain an insurance policy which, within the limits and subject to the terms and conditions thereof, covers certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of our company.

**Item 7.** **Exemption from Registration Claimed.**

Not applicable.

**Item 8.** **Exhibits.**

See the Exhibit Index below for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

**Item 9.** **Undertakings.**

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed the value we registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (1)(i) and (1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**INDEX TO EXHIBITS** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit**<br>**Number** | <br>**Exhibit Description** | **Form** | **Exhibit** | **Filing Date** |
| 4.1 | [Amended and Restated Certificate of Incorporation.](https://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm) | 8-K | 3.1 | July 19, 2019 |
| 4.2 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation.](https://www.sec.gov/Archives/edgar/data/1280776/000119380524000341/e619340_ex3-1.htm) | 8-K | 3.1 | March 8, 2024 |
| 4.3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> [Third Amended and Restated Bylaws.](https://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm) | 8-K | 3.2 | July 17, 2019 |
| 5.1\* | [Opinion of Dentons US LLP.](e664796_ex5-1.htm) |  |  |  |
| 23.1\* | [Consent of Baker Tilly US, LLP.](e664796_ex23-1.htm) |  |  |  |
| 23.2\* | [Consent of Dentons US LLP (included in Exhibit 5.1).](e664796_ex5-1.htm) |  |  |  |
| 24.1\* | [Power of Attorney (contained on signature page hereto).](#poa) |  |  |  |
| 107\* | [Filing Fee Table.](e664796_ex107.htm) |  |  |  |
| 99.1 | [2019 Omnibus Equity Incentive Plan, as amended](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000787/e664589_ex10-1.htm) | 8-K | 10.1 | June 4, 2025 |

---

\* Filed herewith.

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 27th day of August 2025.

---

| | |
|:---|:---|
| **IMMUNIC, INC.** | **IMMUNIC, INC.** |
| (Registrant) | (Registrant) |
| By: | /s/ Daniel Vitt |
|  | Name: Daniel Vitt |
|  | Title: Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel Vitt and Glenn Whaley, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign this Registration Statement on Form S-8 of Immunic, Inc., and any or all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Daniel Vitt | Chief Executive Officer and Director | August 27, 2025 |
| Daniel Vitt | *(Principal Executive Officer)* |  |
| /s/ Glenn Whaley | Chief Financial Officer |  |
| Glenn Whaley | *(Principal Financial and Accounting Officer)* | August 27, 2025 |
| /s/ Duane D. Nash | Executive Chairman of the Board | August 27, 2025 |
| Duane D. Nash |  |  |
| /s/ Tamar Howson | Director | August 27, 2025 |
| Tamar Howson |  |  |
| /s/ Joerg Neermann | Director | August 27, 2025 |
| Joerg Neermann |  |  |
| /s/ Barclay A. Phillips | Director | August 27, 2025 |
| Barclay A. Phillips |  |  |
| /s/ Richard Rudick | Director | August 27, 2025 |
| Richard Rudick |  |  |
| /s/ Simona Skerjanec | Director | August 27, 2025 |
| Simona Skerjanec |  |  |
| /s/ Maria Tornsen | Director | August 27, 2025 |
| Maria Tornsen |  |  |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![](image1.jpg) | Dentons US LLP<br> 1221 Avenue of the Americas<br> New York, NY 10020-1089<br>P +1 212 768 6700<br> F +1 212 768 6800 |

---

August 27, 2025

Immunic, Inc. 1200 Avenue of the Americas, Suite 200 New York, NY 10036

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Immunic, Inc. (the "<u>Company</u>"), a corporation organized under the laws of the State of Delaware, in connection with the registration under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), of the issuance of up to 7,000,000 shares (the "<u>Shares</u>") of the Company's common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), pursuant to the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as amended (as amended, the "<u>2019 Plan</u>"), on a Registration Statement on Form S-8 being filed on the date hereof by the Company with the U.S. Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>") (such registration statement, as it may be amended, the "<u>Registration Statement</u>").

We are delivering this opinion to you in accordance with your request and in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.

In connection with rendering this opinion, we have examined originals, certified copies or copies otherwise identified as being true copies of the following:

&nbsp;&nbsp;&nbsp;&nbsp;1. the Registration Statement, together with the exhibits filed as a part thereof and including any documents
incorporated by reference therein;

&nbsp;&nbsp;&nbsp;&nbsp;2. The Amended and Restated Certificate of Incorporation of the Company, as amended and restated;

&nbsp;&nbsp;&nbsp;&nbsp;3. the Third Amended and Restated Bylaws of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;4. the 2019 Plan;

&nbsp;&nbsp;&nbsp;&nbsp;5. corporate resolutions and proceedings of the Company relating to its proposed issuance of the Shares;
and

&nbsp;&nbsp;&nbsp;&nbsp;6. such other instruments and documents as we have deemed relevant or necessary in connection with our opinions
set forth herein.

We have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as certified, facsimile or photostatic copies, and the authenticity of the originals of such copies. In addition, for purposes of this opinion, we have assumed that a sufficient number of authorized but unissued shares of the Company's Common Stock will be available for issuance when the Shares are issued.

Based on the foregoing, and subject to the limitations, qualifications, exceptions and assumptions expressed herein, we are of the opinion, assuming no change in the applicable law or pertinent facts and having due regard for such legal considerations as we deem relevant, that the Shares, when issued and paid for in accordance with the terms of the 2019 Plan, will be validly issued, fully paid and non-assessable.

We express no opinion as to the laws of any jurisdiction other than the State of New York (excluding local laws), Delaware corporate law and the federal laws of the United States of America.

---

| | |
|:---|:---|
| ![](image1.jpg) | Dentons US LLP<br> 1221 Avenue of the Americas<br> New York, NY 10020-1089<br>P +1 212 768 6700<br> F +1 212 768 6800 |

---

This opinion is solely for your benefit and may not be furnished to, or relied upon by, any other person or entity without the express prior written consent of the undersigned, however, we hereby consent to the use of our opinion as herein set forth as an exhibit to the Registration Statement. We do not, by giving such consent, admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations of the Commission thereunder.

Very truly yours,

## Exhibit 23.1

**EXHIBIT 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Immunic, Inc. of our report dated March 31, 2025, relating to the consolidated financial statements of Immunic, Inc., which appears in the Annual Report on Form 10-K for the year ended December 31, 2024, which includes an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 1 to the consolidated financial statements.

Minneapolis, Minnesota

August 27, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Immunic, Inc.**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Equity | Common Stock, par value $0.0001 per share | (1) | Other | 7000000 | $0.8970 | $6279000.00 | 0.0001531 | $961.31 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $6279000.00 |  | 961.31 |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  |  |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $961.31 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price of the Registrant's common stock are based upon the average of the high and low prices of the Common Stock on August 20, 2025, as reported on the Nasdaq Stock Market, which date is within five business days prior to the filing of this Registration Statement. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as amended, by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of common stock. The Registrant does not have any fee offsets.